Xiaoxia Chen

Xiaoxia Chen

Auto-generated profile, based on publicly available information

Xiaoxia Chen


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MHMuren Hu
Muren Hu
HYHongmei Yang
Hongmei Yang
SXShuai Xue
Shuai Xue
ZWZhiyuan Wang
Zhiyuan Wang
YLYangkun Li
Yangkun Li
XCXiaoxia Chen
Xiaoxia Chen
Activation of the cGAS-STING pathway represents a strategy for cancer immunotherapy. However, the efficacy of STING agonists is not only hindered by delivery barriers (poor stability and targeting), but also by tumor-intrinsic signaling dysfunctions, notably STING depletion and lactate-driven cGAS-STING pathway inhibition. Here, we develop a tumor-targeted programmable DNA nanosphere (DNS-STING-STP) that potentiates colorectal cancer immunotherapy through the restoration of STING signaling and alleviation of lactate-associated immunosuppression. DNS-STING-STP is generated via one-pot manganese-mediated rolling circle amplification, integrating interferon-stimulatory DNA motifs (ISD-dsDNA), a STING protein lacking the transmembrane (TM) domain (STINGΔTM), stiripentol, and the nucleolin-targeting AS1411 aptamer into a nanoplatform. Following nucleolin-mediated uptake, the nanoassembly exploits manganese-facilitated lysosomal escape to release its cargoes into the cytosol. Stiripentol alleviates lactate-mediated suppression of cGAS activity, while ISD-dsDNA, manganese ions, and STINGΔTM synergistically augment cGAS-STING pathway. DNS-STING-STP triggered dendritic cell maturation and cytokine secretion in vitro. In vivo, it reprogrammed the immunosuppressive tumor microenvironment by expanding effector cells (DCs, CD8+ T, NK cells) and depleting suppressive myeloid cells. Furthermore, DNS-STING-STP synergized with anti-PD-L1 blockade, resulting in colorectal tumor suppression and extended survival. Thus, this work establishes a strategy that couples targeted agonism with the correction of tumor-intrinsic cGAS-STING pathway dysfunction to amplify antitumor immunity.